Welcome to California Research Institute

At California Research Institute, we are dedicated to advancing medical knowledge and improving patient care through clinical research. Below, you'll find information about our currently enrolling studies. If you or someone you know is interested in participating, please contact us for more details.

We are currently enrolling for the following clinical research studies:

Non-Oncology

Study 1: Systemic Lupus Erythematosus (SLE)

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Obexelimab In Patients With Systemic Lupus Erythematosus.

ClinicalTrials.gov ID: NCT06559163

Study 2: Systemic Lupus Erythematosus (SLE)

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Cenerimod in Adult Subjects With Moderate-to-Severe Systemic Lupus Erythematosus (SLE) on Top of Background Therapy.

 ClinicalTrials.gov ID: NCT05648500

Oncology

Study 1: Breast Cancer

An Open-label Multicenter Phase 1b-2 Study of Elacestrant in Combination with Abemaciclib in Women and Men with Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breast Cancer.

ClinicalTrials.gov ID: NCT05386108

Study 2: Breast Cancer

A Phase 3 Randomized, Open-Label Study Of Op-1250 Monotherapy Vs Standard Of Care For The Treatment Of Er+ Her2– Advanced Or Metastatic Breast Cancer Following Endocrine And Cdk 4/6 Inhibitor Therapy.

ClinicalTrials.gov ID: NCT06016738

Study 3: Breast Cancer

A Randomized Phase 2 Non-inferiority Trial of (Z)-endoxifen + Goserelin Versus Exemestane + Goserelin as Neoadjuvant Treatment for Premenopausal Women with ER+, HER2-, Ki-67 > 10% Breast Cancer and a Single Arm Phase 2 Study of (Z)-endoxifen as Neoadjuvant Treatment for Premenopausal Women with ER+,HER2-, Ki-67.

ClinicalTrials.gov ID: NCT05607004

Study 4: Solid Tumors (Breast Cancer and Mesothelioma)

A Phase 1/2a, Multicenter, Open-Label, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1305 in Subjects with Advanced/Metastatic Solid Tumors.

ClinicalTrials.gov ID: NCT05438329

Study 5: Solid Tumors (Non-Small Cell Lung Cancer)

An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Multicohort, Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors.

ClinicalTrials.gov ID: NCT04198766

Study 6: Prostate Cancer

Randomized Phase 2b Study of ZEN003694 in Combination with Enzalutamide versus Enzalutamide Monotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer.

ClinicalTrials.gov ID: NCT04986423

Study 7: Non-Small Cell Lung Cancer (Squamous NSCLC)

A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer.

ClinicalTrials.gov ID: NCT06246110

Study 8: Non-Small Cell Lung Cancer ( Non Squamous NSCLC)

A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Platinum-based Chemotherapy in Combination with Pembrolizumab, as First-line Therapy in Participants with Locally Advanced Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer.

ClinicalTrials.gov ID: NCT06899126

Study 9: Colorectal Cancer

A Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI with or without Bevacizumab-awwb for Treatment-naïve subjects with Metastatic Colorectal Cancer with KRAS p.G12C Mutation.

ClinicalTrials.gov ID: NCT06252649

Study 10: Myelofibrosis

A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib.

ClinicalTrials.gov ID: NCT06479135

Study 11: Head and Neck Squamous Cell Carcinoma

A study that consists of first-line therapy in patients with unresectable recurrent, or metastatic human papilloma virus 16, PD-L1 + Head and Neck Squamous Cell Carcinoma.

ClinicalTrials.gov ID NCT04534205

Study 11: Cancer

A study is designed to evaluate tumor biomarker/molecular characteristics in blood from cancer patients.

For more information about our clinical trials or to see if you qualify for participation, please contact us today.